<DOC>
	<DOCNO>NCT01868009</DOCNO>
	<brief_summary>Subjects use ELLIPTA™ inhaler DISKUS™ inhaler past 6 month screen participate study . Subjects equal chance follow two group ( 1:1 allocation ) . One group dispense ELLIPTA inhaler Visit 1 use first period ( daily 5 to9 day ) , DISKUS inhaler Visit 2 use second period ( twice daily 5 9 day ) . The group dispense DISKUS inhaler Visit 1 use first period ( twice daily 5 9 day ) , ELLIPTA inhaler Visit 2 use second period ( daily 5 to9 day ) . At end second period , subject complete study answer 7 question assess preference device attribute dose regimen two inhaler . The null hypothesis device preference specific attribute 50 % subject express preference attribute ELLIPTA 50 % NOT express preference attribute ELLIPTA , i.e. , odds prefer ELLIPTA prefer ELLIPTA unity . The null hypothesis dose regimen preference 50 % subject express preference daily dose 50 % express preference daily dose ( prefer twice daily dose preference ) .</brief_summary>
	<brief_title>DISKUS vs. ELLIPTA Device Preference Study Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Informed consent Subject must give sign dated write informed consent participate . Subject understand willing , able , likely comply study procedure restriction . Subject must able read , comprehend , record information English . 2 . Age : &gt; =40 year age Visit 1 3 . Gender : Male female subject 4 . COPD diagnosis subject clinical history COPD accordance definition American Thoracic Society/European Respiratory Society 5 . Severity disease : Subject measure postalbuterol Forced expiratory volume 1 second ( FEV1 ) / Forced vital capacity ( FVC ) ratio &lt; =0.70 Visit 1 Subjects measure postalbuterol FEV1 &lt; =70 % predict normal value calculate use Third National Health Nutrition Examination Survey reference equation Visit 1 . Postbronchodilator spirometry perform approximately 1015 minute subject selfadministered 4 inhalation ( i.e. , total 400 microgram ) albuterol via meter dose inhaler ( MDI ) valvedholding chamber . The FEV1/FVC ratio FEV1 percent predict value calculate investigator site . Documented spirometry measurement meet criterion last 12 month precede Visit 1 acceptable . 6 . Tobacco use : current former smoker Smokers define smoke 10 packyears cigarette . Note : Pipe and/or cigar use use calculate packyear history . Number pack year = ( number cigarette per day/20 ) x number year smoke 1 . Previous experience DISKUS inhaler Subjects use DISKUS inhaler ( e.g. , ADVAIR DISKUS , FLOVENT DISKUS® ; participate clinical study fluticasone propionate/salmeterol , component , placebo ) within 6 month ( i.e. , 180 day ) prior Visit 1 . 2 . Previous experience ELLIPTA inhaler Subjects use ELLIPTA inhaler ( e.g. , participate clinical study FF/VI GSK573719/GW642444 [ umeclidinium/vilanterol ] , component , placebo ) within 6 month ( i.e. , 180 day ) prior Visit 1 . 3 . Asthma : Subjects current diagnosis asthma . Subjects prior history asthma eligible current diagnosis COPD . 4 . Poorly control COPD : Subjects symptoms poorly control COPD : Acute worsen COPD manage subject corticosteroid antibiotic require treatment prescribed physician , 4 week prior Visit 1 . Hospitalization due acute worsen COPD within 4 week Visit 1 . Use total 8 puffs/day shortacting symptom relief medication albuterol ipratropium 2 consecutive day 3 day within 7 day immediately precede Visit 1 . Changes COPD symptom sign , suggest worsen COPD health status Visit 1 . 5 . Other diseases/abnormalities : Subjects current evidence uncontrolled clinically significant disease . Significant define disease , opinion investigator , would put safety subject risk participation , would affect efficacy safety analysis disease/condition exacerbate study . Subjects suspect evidence oropharyngeal candidiasis exclude study . Note : subject develop oropharyngeal candidiasis study treat discretion investigator . 6 . Drug/food allergy : Subjects history hypersensitivity component inhalation powder ( e.g. , lactose , magnesium stearate ) . In addition , subject history severe milk protein allergy , opinion investigator , contraindicate subject 's participation also exclude . 7 . Drug/alcohol abuse : Subjects know suspected alcohol drug abuse Visit 1 opinion investigator could interfere subject 's proper completion protocol requirement 8 . Medication prior spirometry : Subjects medically unable unwilling withhold COPD medication prior spirometry test Visit 1 . Subjects , document spirometry measurement meet specified Inclusion Criterion last 12 month precede Visit 1 , undergo repeat spirometry Visit 1 . 9 . Investigational drug device : Subjects participate interventional study use investigational drug device within 30 day 5 half life , whichever longer , prior Visit 1 10 . Affiliation investigator site : Study investigator , subinvestigators , study coordinator , employee participate investigator immediate family member aforementioned excluded participating study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>fluticasone furoate</keyword>
	<keyword>COPD</keyword>
	<keyword>ELLIPTA</keyword>
	<keyword>fluticasone propionate</keyword>
	<keyword>DISKUS</keyword>
	<keyword>Novel Dry Powder Inhaler ( NDPI )</keyword>
	<keyword>device preference</keyword>
	<keyword>salmeterol</keyword>
	<keyword>vilanterol</keyword>
</DOC>